Howard Bruce Urnovitz

Calypte Biomedical Corp. develops, manufactures and distributes vitro testing products, which improves the diagnosis of Human Immunodeficiency Virus infection, sexually transmitted diseases and other chronic diseases. The company's product line includes both point-of-case rapid tests and the BED incidence test. Calypte Biomedical was founded in 1988 and is headquartered in Portland, OR.

Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA.

FBB Biomed, Inc. operates as a biotech company. It focuses on the development of genetics, bioinformatics, and RNA virology for combating diseases. The firm's platform technology addresses the market for RNA diagnostics and therapeutics. The company was founded by Howard Bruce Urnovitz and Julien Rey and is headquartered in Coralville, IA.